Literature DB >> 25687183

MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1.

Shuxiang Hu1, Ruiyang Tao, Shouyu Wang, Chaoqun Wang, Xiankun Zhao, Hua Zhao, Lijuan Li, Shaohua Zhu, Yan He, Xinghong Jiang, Yuzhen Gao.   

Abstract

It has been reported that miR-21 is upregulated in hepatocellular carcinoma (HCC), and overexpressed miR-21 plays a key role in promoting cell cycle progression, reducing cell death and favoring angiogenesis and invasion. Overexpression of hepatocellular carcinoma, downregulated 1 (HEPN1) exhibits an antiproliferative effect on HepG2 cells, suggesting that silencing of HEPN1 may contribute to carcinogenesis of hepatocytes. In silico analysis revealed that HEPN1 may be a potential target of miR-21. Using quantitative reverse transcription PCR and Western blot, we found that HEPN1 was strikingly downregulated in both mRNA (fold change was 33.5, P < 0.0001) and protein levels in human HCC tumor tissues, in comparison with the adjacent non-tumor tissues. More importantly, the expression level of HEPN1 was inversely correlated with the expression of miR-21 in HCC (R (2) = 0.442, P < 0.0001). The combination between the 3' untranslated region (UTR) of HEPN1 with miR-21 was experimentally verified by a miRNA luciferase reporter approach. The suppressed cell proliferation upon stimulation of miR-21 inhibitor could be partially abolished by knocking down HEPN1, so inhibition of miR-21 expression in HCC cells profoundly suppressed cell proliferation partially by upregulating HEPN1 expression. Taken together, the current study suggested an underlying mechanism that miR-21 directly target HEPN1 and inhibit its expression during the carcinogenesis of HCC. HEPN1 may thus be a candidate as a therapeutic target for patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25687183     DOI: 10.1007/s13277-015-3213-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  4 in total

1.  Silencing of HEPN1 is responsible for the aggressive biological behavior of pituitary somatotroph adenomas.

Authors:  Hu Peng; Jingping Fan; Jian Wu; Juntian Lang; Junyu Wang; Huanhai Liu; Shuwei Zhao; Jianchun Liao
Journal:  Cell Physiol Biochem       Date:  2013-03-08

2.  Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer.

Authors:  Shuo You; Rui Li; Dongkyoo Park; Maohua Xie; Gabriel L Sica; Ya Cao; Zhi-Qiang Xiao; Xingming Deng
Journal:  Mol Cancer Ther       Date:  2013-12-20       Impact factor: 6.261

3.  Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.

Authors:  François Vaillant; Delphine Merino; Lily Lee; Kelsey Breslin; Bhupinder Pal; Matthew E Ritchie; Gordon K Smyth; Michael Christie; Louisa J Phillipson; Christopher J Burns; G Bruce Mann; Jane E Visvader; Geoffrey J Lindeman
Journal:  Cancer Cell       Date:  2013-07-08       Impact factor: 31.743

4.  Small-molecule Bax agonists for cancer therapy.

Authors:  Meiguo Xin; Rui Li; Maohua Xie; Dongkyoo Park; Taofeek K Owonikoko; Gabriel L Sica; Patrick E Corsino; Jia Zhou; Chunyong Ding; Mark A White; Andrew T Magis; Suresh S Ramalingam; Walter J Curran; Fadlo R Khuri; Xingming Deng
Journal:  Nat Commun       Date:  2014-09-17       Impact factor: 14.919

  4 in total
  5 in total

1.  MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma.

Authors:  Yue-Yuan Lai; Fei Shen; Wen-Song Cai; Ji-Wei Chen; Jian-Hua Feng; Jie Cao; Huan-Qing Xiao; Guang-Hui Zhu; Bo Xu
Journal:  Tumour Biol       Date:  2016-08-19

2.  Long Non-Coding RNA NEAT1 Promoted Hepatocellular Carcinoma Cell Proliferation and Reduced Apoptosis Through the Regulation of Let-7b-IGF-1R Axis.

Authors:  Qin Liu; Hexian Shi; Jianbo Yang; Ning Jiang
Journal:  Onco Targets Ther       Date:  2019-11-29       Impact factor: 4.147

Review 3.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

4.  High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1.

Authors:  Yu-Shui Ma; Ting-Miao Wu; Zhong-Wei Lv; Gai-Xia Lu; Xian-Ling Cong; Ru-Ting Xie; Hui-Qiong Yang; Zheng-Yan Chang; Ran Sun; Li Chai; Ming-Xiang Cai; Xiao-Jun Zhong; Jian Zhu; Da Fu
Journal:  Oncotarget       Date:  2017-02-14

5.  High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma.

Authors:  Peng Sheng Yi; Jian Shui Li
Journal:  Mol Clin Oncol       Date:  2018-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.